Abstracts Archive - Page 581 of 2607 - ACR Meeting Abstracts

Abstract Number: 1461 • ACR Convergence 2022
The Frequency of Systemic Lupus Erythematosus in Patients with Immune Thrombocytopenic Purpura: A Systematic Meta-analysis
Omer Pamuk¹ and Sarfaraz Hasni², ¹NIH/NIAMS, Bethesda, MD, ²NIAMS/NIH, Bethesda, MD
Background/Purpose: Immune thrombocytopenic purpura (ITP) is an organ-specific autoimmune disease and its etiopathogenetic mechanisms are suggestive of systemic autoimmune diseases (SAD) such as systemic lupus…
Abstract Number: 1473 • ACR Convergence 2022
Unsupervised Clustering of Lupus Patient-Reported Outcome Data Identifies Patient Groups with Differences in SLEDAI and Physician Global Assessment
Jack Zent¹, Kristy Bell², Brooke Williams², Prathyusha Bachali³ and Peter Lipsky⁴, ¹AMPEL BioSolutions LLC, Leesburg, VA, ²AMPEL BioSolutions LLC, Charlottesville, VA, ³AMPEL BioSolutions, Redmond, WA, ⁴AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with heterogeneous clinical presentations. Patient-reported outcomes (PROs) can aid in the measurement of the burden of…
Abstract Number: 1474 • ACR Convergence 2022
Quinolinic Acid, a Kynurenine/Tryptophan Pathway Metabolite, Correlates with Abnormalities in Brain Structure and Function in SLE
Erik Anderson, Chris Tang, An Vo, Cynthia Aranow, Bruce Volpe, Betty Diamond and Meggan Mackay, Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Stimulation of the kynurenine/tryptophan pathway by interferons alpha and gamma, both known contributors to SLE pathogenesis, leads to a potentially neurotoxic imbalance of pathway…
Abstract Number: 1464 • ACR Convergence 2022
Patients with Late-onset-Systemic Lupus Erythematosus Have Different Disease Presentations
Ganiat Adeogun, Alex Camai, Sarah Green and April Barnado, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Systemic lupus erythematosus (SLE) predominantly affects females of reproductive age but can affect patients later in life. Late-onset (LO)-SLE is defined as SLE diagnosed…
Abstract Number: 1472 • ACR Convergence 2022
Autoantibodies Against Tripartite-Motif 72 Protein (TRIM72) in Systemic Lupus Erythematosus Patients and in a Lupus Mouse Models with Myocarditis, Can Compromise Membrane Repair in Cardiomyocytes Potentially Contributing to Cardiovascular Disease Progression
Kassidy Banford¹, hannah Bulgart¹, Shane Bruckner², Stacy Ardoin³, Noah Weisleder² and Wael Jarjour², ¹The Ohio State University Wexner Medical Center, Columbus, OH, ²The Ohio State University, Columbus, OH, ³The Ohio State College of Medicine, Columbus, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that typically manifests in multiple organs, with some of the most significant complications occurring in the…
Abstract Number: 1485 • ACR Convergence 2022
Characterization of Regulatory Receptors on Plasmacytoid Dendritic Cells in Lupus
Mark Jensen¹, Ilona Nln¹, Taro Iwamoto², Jessica Dorschner³, Danielle Vsetecka³, Jacqueline Paredes¹, Ruth Fernandez Ruiz⁴, Theresa Wampler Muskardin⁵ and Timothy Niewold¹, ¹Hospital for Special Surgery, New York, NY, ²Chiba University, New York, NY, ³Mayo Clinic, Rochester, ⁴Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁵Colton Center for Autoimmunity, NYU School of Medicine, New York, NY
Background/Purpose: To characterize regulatory surface receptors on blood plasmacytoid dendritic cells (PDCs) of lupus patients and controls to determine if receptor expression and function associates…
Abstract Number: 1479 • ACR Convergence 2022
Association of Neuromyelitis Optica and Systemic Lupus Erythematosus: Analysis of National Inpatient Sample 
Faria Sami and Shilpa Arora, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL
Background/Purpose: Neuromyelitis Optica (NMO), also known as Devic's disease, is a rare inflammatory demyelinating disorder causing myelitis and optic neuritis. While there have been reports…
Abstract Number: 1481 • ACR Convergence 2022
Dementia in Adults with Systemic Lupus Erythematosus 65 Years of Age and Above: A National Administrative Claims Data Analysis
Sarah Lieber¹, Musarrat Nahid², Iris Navarro-Millan², Mangala Rajan², Sebastian Sattui³, Robyn Lipschultz¹, M. Carrington Reid² and Lisa Mandl¹, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY, ³University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Systemic lupus erythematosus (SLE) has been associated with increased risk of dementia relative to age-matched comparators without systemic rheumatic disease (SRD) in non-US-based samples…
Abstract Number: 1477 • ACR Convergence 2022
Prevalence and Risk Factors of Fragility Fractures in Systemic Lupus Erythematosus: A Longitudinal Study over 12 Years
Chi Chiu Mok¹, Kar Li Chan², Ling Yin Ho³ and Chi Hung To⁴, ¹Tuen Mun Hospital, Hong Kong, China, ²Tuen Mun Hospital, Tsing Yi, Hong Kong, China, ³Tuen Mun Hospital, Hong Kong SAR, China, ⁴Hospital Authority, Hong Kong, Hong Kong
Background/Purpose: To study the prevalence and risk factors of fragility fractures in a longitudinal cohort of patients with SLE.Methods: All patients who fulfilled ≥4 1997…
Abstract Number: 1488 • ACR Convergence 2022
Incremental Healthcare Resource Utilization and Costs of Herpes Zoster in Patients with Psoriatic Arthritis: A Retrospective Cohort Study
David Singer¹, Philippe Thompson-Leduc², Siyu Ma³, Deepshekhar Gupta⁴, Wendy Cheng⁵, Selvam Sendhil⁶, Manasvi Sundar⁶, Ella Hagopian⁵, Mei Sheng Duh⁷ and Sara Poston¹, ¹GSK, Philadelphia, PA, ²Analysis Group, Inc., Montréal, QC, Canada, ³GSK/Tufts Medical Center, Boston, MA, ⁴Analysis Group, Inc., Menlo Park, CA, ⁵Analysis Group, Inc., Boston, MA, ⁶Analysis Group, Inc., Los Angeles, CA, ⁷Analysis Group Inc, Boston, MA
Background/Purpose: Patients with psoriatic arthritis (PsA) may be at increased risk of herpes zoster (HZ). HZ can involve a painful dermatomal rash and lead to…
Abstract Number: 1487 • ACR Convergence 2022
Differentiation of Therapeutic Antibodies Targeting Interleukin (IL)-23
James Krueger¹, Kilian Eyerich², Dennis McGonagle³, Carrie Greving⁴, Kacey Sachen⁴, Deepa Hammaker⁴, Phuc Bao⁴, Eilyn Lacy⁴, M. Merle Elloso⁵, Yevgeniya Orlovsky⁵, Iain B McInnes⁶ and Anne Fourie⁷, ¹The Rockefeller University, New York, NY, ²Technical University, Munich, Germany / Karolinska Institute, Stockholm, Sweden, ³University of Leeds, Leeds, UK, Leeds, United Kingdom, ⁴Janssen Research & Development, LLC, San Diego, CA, USA, San Diego, ⁵Janssen Research and Development, LLC, Spring House, PA, ⁶Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ⁷Janssen Research & Development, LLC, San Diego, CA, USA, San Diego, CA
Background/Purpose: Clinically relevant differences between therapeutic antibodies against the same target may relate to their unique molecular attributes. Differences in therapeutic profiles across the domains…
Abstract Number: 1489 • ACR Convergence 2022
Incidence of Herpes Zoster Events After the Three Doses of the BNT162b2 mRNA Vaccine in Patients with Spondyloarthritis
Devy Zisman¹, Noa Hayat¹, Amir Haddad², Joy Feld³, Tal Gazitt¹, Idit Lavi¹, Ilan feldhamer⁴, ARNON DOV COHEN⁴ and Walid Saliba¹, ¹Carmel Medical Center, Haifa, Israel, ²Carmel Medical Centre, Haifa, Israel, ³Carmel and Zvulun Medical Centre, Haifa, Israel, ⁴Clalit Health Services, Tel Aviv, Israel
Background/Purpose: The importance and efficacy of anti COVID-19 vaccine in coping with the pandemic are well established, but inconsistencies remain in the data regarding side…
Abstract Number: 1430 • ACR Convergence 2022
Time to First Remission and Prevalence of Sustained Remission After Etanercept Biosimilar (ETA-B) or Originator (ETA-O) Initiation in Rheumatoid Arthritis
Cristiano Moura¹, Luck Lukusa¹, Laura Yan¹, Walter P Maksymowych², Denis Choquette³, Gilles Boire⁴ and Sasha Bernatsky¹, ¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁴Universite de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: The first biosimilar etanercept (ETA-B) was approved in Canada in 2016, but real-world data comparing the effectiveness of ETA-B versus its equivalent originator (ETA-O)…
Abstract Number: 1380 • ACR Convergence 2022
Development of Core and Expanded Datasets to Align Registries and Advance International Collaborative Research for Childhood-onset Systemic Lupus Erythematosus
Rebecca Sadun¹, Laura Lewandowski², Alexandre Belot³, Eve Smith⁴ and Jennifer Cooper⁵, ¹Duke University, Durham, NC, ²NIAMS, NIH, Bethesda, MD, ³Hospices Civils de Lyon, Collonges au mont d'or, France, ⁴University of Liverpool, Liverpool, United Kingdom, ⁵University of Colorado/Children's Hospital Colorado, Denver, CO
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) occurs in approximately 20% of all SLE cases. cSLE is has a worse prognosis than adult-onset SLE, often requiring…
Abstract Number: 1236 • ACR Convergence 2022
Reduced Inflammation Following 4-weeks TNF-α Inhibitor Treatment Restore Aberrant Cerebral Pain Processing in Rheumatoid Arthritis Patients: A Randomized Double-Blind Placebo-Controlled fMRI Study
Angelica Sandström¹, Peter Fransson², Reem Altawil³, Eva Kosek⁴ and Jon Lampa³, ¹Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Department of Neuroradiology, Karolinska University Hospital, Stockholm, Sweden; Department of Radiology, Massachusetts General Hospital, Boston, MA, ²Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Department of Neuroradiology, Karolinska University Hospital, Stockholm, Sweden, ³Department of Medicine, Rheumatology Unit, Center for Molecular Medicine (CMM), Karolinska Institutet, Stockholm, Sweden; Department of Gastroenterology, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden, ⁴Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Department of Neuroradiology, Karolinska University Hospital, Stockholm, Sweden; Department of Surgical Sciences/Pain Research, Uppsala University, Uppsala, Sweden
Background/Purpose: The purpose with this study was to investigate whether the effects of a 4-week treatment with adalimumab (Humira™) could change previously reported aberrations in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].